INMD InMode Ltd. Annual reports only
Electromedical & Electrotherapeutic Apparatus · Nasdaq · SEC CIK 1742692 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY-6.2%
TTM net income YoY-48.2%
TTM EPS YoY-36.4%
Revenue 3-yr CAGR-6.6%
Net income 3-yr CAGR-16.6%
Margins
Gross margin78.5%
Operating margin23.0%
Net margin25.3%
FCF margin22.7%
EBITDA margin23.2%
Returns
ROE13.5%
ROA12.1%
ROIC (approx.)15.6%
Asset turnover0.48x
Leverage & solvency
Liabilities / assets10.9%
Debt / equity0.00x
Current ratio9.88x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.91x
Accruals ratio1.1%
Payout ratio—
Capex / revenue0.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2025*2025-12-31 | FY2024*2024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $370.50M | $394.82M | $492.05M | $454.27M | $357.56M |
| Cost of revenue | $79.53M | $77.75M | $80.71M | $73.48M | $53.59M |
| Gross profit | $290.97M | $317.07M | $411.34M | $380.79M | $303.97M |
| R&D expense | $13.32M | $13.14M | $13.41M | $12.43M | $9.53M |
| SG&A expense | $11.69M | $10.03M | $9.23M | $9.93M | $8.41M |
| Operating income | $85.39M | $112.53M | $195.66M | $197.85M | $167.48M |
| Pretax income | $110.33M | $143.47M | $217.27M | $201.47M | $168.00M |
| Income tax | $16.50M | -$37.81M | $19.35M | $39.95M | $2.93M |
| Net income | $93.83M | $181.28M | $197.92M | $161.52M | $164.97M |
| EBITDA | $86.08M | $113.26M | $196.28M | $198.53M | $167.99M |
| EPS (basic) | 1.45 | 2.29 | 2.37 | 1.96 | 2.03 |
| EPS (diluted) | 1.43 | 2.25 | 2.30 | 1.89 | 1.92 |
| Weighted avg. shares (diluted) | 65.44M | 80.60M | 85.95M | 85.40M | 86.02M |
| Banking | |||||
| Net interest income | — | — | $4.71M | $1.21M | -$1.22M |
| Balance sheet | |||||
| Cash & equivalents | $302.54M | $155.33M | $144.41M | $97.54M | $68.14M |
| Short-term investments | $83.63M | $267.69M | $373.65M | $374.59M | $294.53M |
| Receivables | $43.50M | $36.34M | $42.36M | $27.00M | $20.24M |
| Inventory | $74.05M | $59.55M | $45.09M | $39.90M | $21.03M |
| Current assets | $698.62M | $714.45M | $845.33M | $629.37M | $470.11M |
| PP&E, net | $2.60M | $2.32M | $2.38M | $2.30M | $1.40M |
| Total assets | $766.43M | $785.67M | $863.29M | $644.41M | $478.54M |
| Current liabilities | $70.74M | $69.85M | $64.14M | $82.02M | $51.85M |
| Total liabilities | $83.23M | $81.85M | $75.91M | $89.79M | $62.74M |
| Shareholders' equity | $683.20M | $703.81M | $787.37M | $554.62M | $415.80M |
| Shares outstanding | 63.36M | 69.56M | 83.98M | 82.54M | 82.98M |
| Cash flow statement | |||||
| Operating cash flow | $85.26M | $132.66M | $176.83M | $181.58M | $174.88M |
| Capital expenditure | $972,000 | $669,000 | $705,000 | $1.57M | $939,000 |
| Free cash flow | $84.28M | $132.00M | $176.12M | $180.00M | $173.95M |
| Investing cash flow | $186.03M | $162.21M | -$136.06M | -$109.47M | -$160.11M |
| Financing cash flow | -$126.06M | -$282.77M | $5.50M | -$41.09M | -$15.02M |
| Depreciation & amortization | $695,000 | $728,000 | $623,000 | $680,000 | $517,000 |
| Stock-based compensation | $11.13M | $16.57M | $23.60M | $24.45M | $11.96M |
| Share buybacks | $127.44M | $285.38M | $0 | $42.64M | $35.37M |
Free plan shows the latest 5 periods; Pro shows all 9 🔒
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.